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Abstract
Objectives To investigate the safety and tolerability of gado-
butrol at the recommended dose in patients requiring contrast-
enhanced magnetic resonance imaging/angiography (MRI/
MRA) in the routine setting.
Methods GARDIAN prospectively enrolled 23,708 patients
undergoing routine gadobutrol-enhanced MRI/MRA for ap-
proved indications at 272 study centres in Europe, Asia, North
America, and Africa and monitored for adverse events.
Results Median gadobutrol dose was 0.11 mmol/kg body
weight. The overall incidence of adverse drug reactions
(ADRs) was 0.7 % (n=170 patients), with similar incidences
in patients with renal impairment or cardiac disease, from
different geographic regions and in different gadobutrol dose
groups. Patients at risk for contrast media reaction had an
ADR incidence of 2.5 %. Five patients (0.02 %) experienced
serious adverse events, four were drug-related. One patient
experienced a fatal anaphylactoid shock, assessed to be related
to injection of gadobutrol. The contrast quality of gadobutrol-
enhanced images was rated by treating physicians as good or
excellent in 97 % cases, with similar ratings in all patient
subgroups and indications.
Conclusions The GARDIAN study shows that gadobutrol at
the recommended dose is well tolerated across a large, diverse
patient population.
Key points
• Gadobutrol at recommended dose shows low rates of ad-
verse drug reactions
• Gadobutrol demonstrates a uniform safety profile across
diverse patient groups
• Gadobutrol provides excellent contrast quality in routine
practice
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GARDIAN Gadovist® in Routine Diagnostic MRI –
Administration in Non-selected Patients
GBCA Gadolinium-based contrast agents
Gd3+ Gadolinium ion
MedDRA Medical Dictionary for Regulatory Activities
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
NSF Nephrogenic systemic fibrosis
SAE Serious adverse event
Introduction
Gadolinium-based contrast agents (GBCAs) enhance tis-
sue contrast in magnetic resonance imaging (MRI) and are
an essential tool for diagnosis in a range of indications [1,
2]. Gadobutrol (Gd-DO3A-butrol, Gadovist®, Gadavist®)
is a non-ionic, macrocyclic GBCA with high T1-relaxivity
and is marketed as a 1 mmol/mL gadolinium concentra-
tion [3, 4]. The higher-concentration formulation of gad-
obutrol compared to almost all other marketed GBCAs
(typically 0.5 mmol/mL) may theoretically influence the
diagnostic efficacy of the compound in first-pass dynamic
techniques, since the higher concentration alters delivery
of gadolinium [5, 6]. Doses of gadobutrol up to 0.3 mmol/
kg BW are approved in some regions for specific indica-
tions in adults. Gadobutrol rapidly distributes into the ex-
tracellular space following infusion and is eliminated in-
tact by glomerular filtration [7].
The macrocyclic chemical structure contributes to the high
kinetic stability of gadobutrol [8] compared with linear con-
trast agents [9], and is associated with a lower propensity to
release gadolinium ions (Gd3+). European, US, and other
guidelines categorize gadobutrol within the lowest risk cate-
gory for nephrogenic systemic fibrosis (NSF) [1, 10–12].
Clinical and observational studies on a range of indications
in adults and children have demonstrated gadobutrol to be
efficacious with a favourable safety and tolerability profile
[13–15]. At the request of the European Medicines Agency
(EMA), a prospective, multicentre, non-interventional study,
GARDIAN (Gadovist® in Routine Diagnostic MRI –
Administration in Non-selected Patients), was initiated to
evaluate the acute safety and tolerability of gadobutrol use in
approved indications in a large patient population in routine
practice, including the age group 2 to 7 years as well as pa-
tients with renal impairment or cardiac disease and patients
considered at risk for contrast media (CM) reactions.
Methods
Trial design
GARDIAN was a phase IV, non-interventional, prospective,
multicentre, post-authorization safety study (PASS). The
study was conducted between August 2010 and April
2013 at 272 study centres in 17 countries in Africa, Asia,
Europe, and North America (NCT01095081). The study pro-
tocol was approved by local ethics committees/institutional
review boards at the respective study sites and was conducted
in accordance with ethical principles consistent with the
Declaration of Helsinki and the International Conference of
Harmonisation guidelines, Good Clinical Practice (ICH-
GCP). The study adhered to guidelines of the EMA, the US
Food and Drug Administration (FDA) [16, 17], local laws and
regulations. Each patient provided written informed consent
prior to study enrolment.
Participants
Male or female adults and children who were scheduled to
undergo cranial or spinal MRI, liver or kidney MRI or MRA
with gadobutrol enhancement were eligible for enrolment.
There were no exclusion criteria beyond the contraindications
in the Summary of Product Characteristics for Gadovist (i.e.
hypersensitivity to the active substance or to any of the
excipients).
Patients received medicinal products according to standard
clinical practice, with no additional diagnostic or monitoring
processes as a result of study participation. Patients with mod-
erate or severe renal impairment (estimated glomerular filtra-
tion rate [eGFR] 30–59 and <30 mL/min/1.73 m2, respective-
ly) were scheduled for follow-up investigation after 3 months,
at the discretion of the treating physician and in accordance
with routine practice. Any skin reactions suggestive of NSF
were compulsorily followed up as potential AEs.
Outcome measures
Patient demographics, medical data (concomitant diseases and
treatments), contrast agent risk factors (including previous
CM reactions), as well as any signs and symptoms or treat-
ments administered for contrast reactions were documented
by the treating physician or nurse in case report forms at the
time of MRI. Information on the CM intravenous injection
(dose, amount) and subjective assessment of contrast-
enhanced image quality were also recorded.
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The primary study endpoint was the overall incidence of
adverse drug reactions (ADRs) and serious adverse events
(SAEs) following gadobutrol administration, including the
rates, severity, and symptoms of events. Adverse events
(AEs) documented by the treating physician or nurse were
categorized as ADRs based on the judgment of the treating
physician. SAEs were defined as events that are medically
important, life-threatening, fatal, or involved hospitalization
or prolongation of current hospitalization, disability/incapaci-
ty, or birth defects.
Secondary study endpoints were the rates, quality, and
symptoms of AEs and ADRs associated with gadobutrol in
special patient groups, including patients at risk for any CM
reaction (i.e. with previous CM reactions, allergies, or bron-
chial asthma), patients with renal impairment or cardiac dis-
ease and patients aged <18 years. ADR rates were analysed
with respect to the gadobutrol dose administered, geographic
region and medical indication. Additionally, the image quality
was rated subjectively by investigators on a four-point scale
(poor, moderate, good, or excellent).
Statistical analyses
Descriptive analyses were performed on continuous and
categorical data. Continuous data were described by me-
dian, mean, standard deviation, maxima, and minima, as
well as upper and lower quartiles. Categorical data were
presented in frequency tables. Safety and tolerability was
assessed by reports of AEs, summarized using the
Medical Dictionary for Regulatory Activities (MedDRA)
coding system (version 13.0) and categorized by
relationship, seriousness, and outcome. Event rates for
AEs/ADRs in patients were calculated as a proportion of
the study population. Analyses were performed on the
total study population (pooled analysis) and in at-risk pa-
tient subgroups. Geographic regions were analysed by
pooling countries into three groups: Asia, Europe, and
BOther^ (Canada and South Africa).
Safety analyses were performed on the safety popula-
tion, which included all subjects assigned to treatment
who received at least one dose of gadobutrol. The efficacy
population included all subjects who underwent MRI/
MRA scans with gadobutrol injection. Statistical analyses
were performed using the software package SAS version
9.2 (SAS Institute, Cary, NC, USA). Significance tests
(χ2-test and Fisher’s exact test) were performed to inves-
tigate differences in the occurrence of ADRs according to
gender and regions.
As a post-approval commitment with the EMA, a study
population of at least 20,000 patients from approximately
200 sites in Europe and Asia was planned, including at least
600 patients aged <18 years (paediatric population) with at
least 100 patients aged 2 to 6 years.
Results
Baseline demographics
A total of 23,775 eligible patients were enrolled in the
GARDIAN study. Of those, 23,708 patients were admin-
istered at least one dose of gadobutrol and were included
Exclusion from safety population





n=11, no informed consent












*11 patients with renal impairment 
Safety population
n=23,708
Fig. 1 Disposition of patients. CRF case report form
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in the safety population (Fig. 1). This patient population
consisted of approximately two thirds Asian (n= 15,923)
and one third white/Caucasian (n= 7,459) patients. Patient
r e c ru i tmen t by coun t ry i s shown in Tab l e 1 .
Approximately one half of patients (48.2 %) were male;
median age was 52 years, with median height, weight, and
body mass index at 165 cm, 65 kg, and 23.8 kg/m2, re-
spectively (Table 2).
A total of 1,060 patients (4.5 %) presented with at least one
risk factor for CM reaction, including a previous CM reaction
(n=105), allergies (n=833), or bronchial asthma (n=253).
Some patients were enrolled at the discretion of the treating
physician due to the following: 1,233 patients (5.2 %) had
concomitant cardiac diseases, and 153 patients (0.6 %) had
renal impairment, with 17 patients receiving dialysis. Of the
patients with renal impairment, 15 had mild (eGFR 60–
90 mL/min/1.73 m2), 100 moderate (eGFR <60 but >30 mL/
min/1.73 m2), and 31 severe renal impairment (eGFR
<30 mL/min/1.73 m2); eGFR was unavailable for seven renal
impairment patients. Eleven follow-up investigations were
documented in patients with renal impairment, at a median
of 95 (±9) days from the time of MRI/MRA. A total of
1,142 (4.8 %) paediatric patients were included in the safety
population, most aged 7 to <18 years (84.9 %). Detailed re-
sults for the paediatric population will be reported elsewhere.
Eleven patients were excluded from the study because they
did not provide informed consent or receive an MRI/MRA
scan; therefore, 23,697 patients were valid for the efficacy
population (Fig. 1).
MRI indications
The majority of MRI scans in the 23,697 patients in the effi-
cacy population were for suspected tumours (54.4 %), follow-
ed by infarction (9.0 %), inflammatory disease (6.3 %), stag-
ing (3.9 %), multiple sclerosis (3.5 %), trauma (2.8 %), and
other indications (19.8 %); data were unavailable for 52 pa-
tients (0.2 %). Investigations included MRI in 16,210 patients
and MRA in 7,269 patients. The central nervous system was
investigated in 62.3 %, the vessels and MRA in 30.7 %, the
liver in 7.4 % and kidneys in 1.6 %. The majority of the 7,269
MRA investigations were applied to the head (59.0 %) or neck
(19.1 %). Since MRA and MRI were often performed togeth-
er, 1,923 patients (8.1 %) had more than one investigation
type.
Gadobutrol dose
The median dose of gadobutrol administered was 0.11 mmol/
kg BW, with more than half the patients (55.7 %) receiving a
dose 0.1–0.2 mmol/kg BW (Table 4). Doses >0.3 mmol/kg
BW (0.4 % of patients) were used according to the clinical
assessment by the treating physician. Rates of administration
of doses >0.3 mmol/kg BWwere similar in at-risk and cardiac
disease subgroups (0.1–0.5 %), while no patients with renal
Table 2 Demographics and baseline characteristics of the study
population (safety population)











































Cardiac concomitant disease 1,233 (5.2)
Renal impairment 153 (0.6)
BMI body mass index; CM contrast media
Table 1 Number of adult and paediatric patients per country (safety
population)
Country Adult Paediatric Total
(n,% by region)
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impairment received these doses. The median injection rate of
gadobutrol was 1.5 mL/s, and an automatic injector was used
in 29 % cases.
Adverse events (primary endpoint)
All patients
Of 23,708 patients in the safety population, 202 (0.9 %) re-
ported 251 AEs, with a maximum reported intensity of mild in
most cases (84.9 %), followed by moderate (12.0 %) and
severe (2.4 %) reported intensity. Onset of AEs occurred with-
in 5 min after gadobutrol injection in 62 % of patients (medi-
an: 3.5 min) or within the next 24 h (35.5 %). No treatment
action was taken for the majority of AEs (75 %) and events
resolved in 94 % of cases; in the remainder, outcome was
unknown or missing in 4.8 %, and recovering/resolving in
0.4 %. There were two events with fatal outcome in the study
population (please see below.)
For these 251 AEs, 215 were categorized as ADRs
occurring in 170 (0.7 %) patients. The maximum report-
ed intensity of ADRs was mild in most cases (83.6 %),
with remaining events categorized as moderate (13.2 %)
or severe (2.3 %). The most commonly documented
ADR was nausea (0.3 %), followed by vomiting
(0.1 %) and dizziness (0.1 %) (Table 3). ADR rates
were 0 .9 % in fema les and 0 .6 % in males
(p= 0.0013, Fisher’s exact test). There were no differ-
ences in ADR rates according to dose of gadobutrol
(Table 4).
Five of the 202 patients with AEs (0.02 %) experienced an
SAE, with events in four patients considered as ADRs by the
treating physician (Table 5). One patient experienced a fatal
anaphylactoid shock. This patient was 76 years old, female,
and received 7.5 mL gadobutrol. After MRI, the patient de-
veloped signs of anaphylaxis, reported as dizziness and cya-
nosis, and was taken to the emergency room, where she also
developed signs of pulmonary oedema. The event was
Table 3 ADRs and non-drug-
related AE incidences,
categorized by system organ
class (safety population)








GI disorders Nauseaa 65 0.27 3 0.01
Vomiting 23 0.10 12 0.05
Salivary hypersecretion 2 0.01 0 0.00
Nervous system
disorders
Dizziness 23 0.10 4 0.02
Headache 3 0.01 2 0.01






9 0.04 1 0.00
Feeling hot 7 0.03 0 0.00
Chest discomfort 3 0.01 0 0.00
Skin and subcutaneous
tissue disorders
Rash 8 0.03 0 0.00
Pruritus 7 0.03 0 0.00
Urticaria 7 0.03 2 0.01




Dyspnoeab 6 0.03 1 0.00
Throat irritation 3 0.01 0 0.00
Cough 2 0.01 0 0.00
Cardiac disorders Tachycardia 2 0.01 0 0.00
Eye disorders Eyelid oedema 2 0.01 0 0.00
Vascular disorders Flushing 2 0.01 0 0.00
a One patient had two AEs (nausea and vomiting); b 24 h after CM administration
ADR adverse drug reaction; AE adverse event; CM contrast media; GI gastrointestinal




Number (%) of patientsa ADR incidence
(%)
Mean dose = 0.12
Median dose = 0.11
≤0.1 8,696 (36.7) 0.61
>0.1 – 0.2 13,207 (55.7) 0.78
>0.2 – 0.3 1,692 (7.1) 0.83
>0.3 101 (0.4) 0
a Information missing for 12 patients (0.05 %)
ADR adverse drug reaction; BW body weight
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assessed as anaphylactic shock related to the administration of
gadobutrol. A second death, unrelated to the study drug, was
reported at least 6 months after the end of study as a result of
progression of glioblastoma. The other three SAEs resolved
after 10–20 min; one patient experienced a transient weak
pulse and hypotension, one patient had breakthrough of epi-
lepsy and one patient had transient laryngeal constriction, dys-
pnoea and nausea.
At-risk patient populations
In the 1,060 patients assessed to be at risk for a CM reaction,
32 (3.0 %) patients experienced at least one AE, including
27 (2.5 %) patients determined by the treating physician
to have an ADR. One patient (0.1 %) experienced an
epileptic episode (grand mal convulsion), which resolved
after 10 min; this was a breakthrough of the disease under
investigation and was assessed to be serious and drug-
related (described above).
One AE (0.7 %) and no ADRs were reported by the
153 patients with renal impairment. The AE was a cardiac
arrest occurring 86 days after gadobutrol administration,
and was rated as serious but not related to gadobutrol
injection. No skin reactions suggestive of NSF were re-
ported in any patient including patients with renal impair-
ment. Among 11 patients with renal impairment followed
up after 3 months, there was one case report of skin-
related signs or symptoms (i.e. Bburning or itching^),
wh ich the pa t i en t r epor t ed as a rou t ine pos t -
haemodialysis symptom. This patient had no musculo-
skeletal or other symptoms suggestive of NSF. The patient
had presented with acute renal impairment prior to MR
examination, but had recovered at follow-up (serum
creatinine = 0.68 mg/dL). Of 1,233 patients with cardiac
disease, 14 (1.1 %) had at least one AE, including 11
patients (0.9 %) with an ADR, all non-cardiac in type.
Paediatric population
Eight out of 1,142 (0.7 %) paediatric patients reported at least
one AE, including 6 (0.5 %) patients experiencing an ADR.
No SAEs were reported in the paediatric population.
Geographic regions
The proportions of patients experiencing AEs in different
geographic regions were: Asia 0.7 % (ratio 1:135),
Europe 1.1 % (1:88) , and Other 0.4 % (1:127)
(p= 0.007, χ2-test). Similarly, the proportions of patients
experiencing ADRs by region were: Asia 0.6 % (1:158),
Europe 0.9 % (1:107), and Other 0.4 % (1:267).
Comparisons of the most common AEs in the different
regions are shown in Table 6. Of the four patients who
experienced a drug-related SAE, two were from Asia
Table 5 Serious AEs and serious
ADRs in individual patients:





A Cardiac arresta >0.1–0.2 Not related Fatal
B Nausea ≤0.1 Related Moderate
B Dyspnoea ≤0.1 Related Moderate
B Laryngeal stenosis ≤0.1 Related Moderate
C Anaphylactic shock >0.1–0.2 Related Fatal
D Pulse pressure decreased >0.1–0.2 Related Severe
D Unresponsive to stimuli >0.1–0.2 Related Severe
D Hypotension >0.1–0.2 Related Severe
E Seizureb >0.1–0.2 Related Moderate
a This cardiac arrest occurred 6 months after gadobutrol administration; b This patient with existing seizure
disorder due to glioblastoma on medication had a breakthrough seizure
AE adverse event; ADR adverse drug reaction; BW body weight; SADR serious ADR.
Table 6 Incidences of common AE (>5 patients in any group),
categorized by region (safety population)
System organ class Asia Europe Other p-value
N= 16,610 N= 6,831 N = 267
n % n % n %
Any AE 123 0.74 78 1.14 1 0.37 0.007a
Nausea 38 0.23 30 0.44 0 0 0.016a
Vomiting 28 0.17 7 0.10 0 0 0.4a
Dizziness 23 0.14 4 0.06 0 0 0.22a
Urticaria 7 0.04 2 0.03 0 0 1.0b
Injection-site reaction 6 0.04 4 0.06 0 0 0.55b
Rash 6 0.04 2 0.03 0 0 1.0b
a χ2 -test; b Fisher’s exact test
AE adverse event
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(<0.1 %) and one each from Europe (<0.1 %) and Other
region (0.4 %).
Medical indications
No relationship was found between the likelihood of an AE,
SAE, or ADR and specific medical indications (data not
presented).
Contrast quality
The contrast quality of gadobutrol was evaluated by treating
physicians as good or excellent in the majority of cases
(97 %), with similar efficacy outcomes in the subgroup pop-
ulations: patients at risk for CM reactions (98 %) and patients
with renal impairment (99 %) or cardiac disease (97 %). For
all medical indications, contrast quality was rated as good or
excellent in 97 % of cases, including infarction (96.6 %), in-
flammatory disease (96.6 %), intracerebral haemorrhage
(99.4 %), multiple sclerosis (98.9 %), staging (95.7 %), sub-
arachnoid haemorrhage (99.5 %), trauma (93.9 %), and tu-
mour (97.3 %). Examples of gadobutrol-enhanced MRA im-
ages in a patient enrolled in GARDIAN are shown in Fig. 2.
Discussion
This prospective, non-interventional study provides the largest
analysis of safety and tolerability of gadobutrol, a macrocy-
clic, non-ionic MRI contrast agent, in routine clinical practice.
Gadobutrol at a median dose of 0.11 mmol/kg BW was well
tolerated, with a favourable safety profile in diverse patient
populations, geographic regions, and dose groups. The con-
trast quality of gadobutrol-enhanced images was good or ex-
cellent in 97 % of cases and in at least 94 % for all patient
subgroups and indications.
The low incidence of ADRs in GARDIAN (0.7 %) is con-
sistent with a previous analysis of gadobutrol (Table 7). In that
analysis, which included 14,299 patients from six post-
marketing observational surveillance studies conducted in
Europe and Canada, the ADR rate was 0.55 % at a mean
gadobutrol dose of 0.16 mmol/kg BW [13]. Another analysis
of 4,549 patients from 34 clinical trials reported a higher ADR
incidence rate of 4.0 % [14], which can be attributed to the
different methodology of data collection in randomized con-
trolled clinical trials – including, for example, a longer follow-
up duration (from 24 h to 7 days after gadobutrol administra-
tion) than in the current study, which followed routine clinical
practice. Generally similar ADR rates have been reported for
other GBCAs (Table 7) [13, 14, 18–22].
GARDIAN included an assessment of the safety of gadobu-
trol in at-risk populations not previously studied in routine clin-
ical practice. Patients at-risk for a CM reaction (i.e. with a
previous CM reaction, allergy, asthma) experienced ADRs at
an incidence of 2.5 %. The incidence of ADRs in patients with
renal impairment (0.0 %) or cardiac disease (0.9 %) and for
paediatric patients (0.5 %) was comparable with the total popu-
lation (0.7 %), and showed no relationship with gadobutrol
dose. Other analyses of gadobutrol studies (referred to above)
found no consistent relationship between AE incidence and
degree of impairment in renal function or cardiac disorders
[14]. Similarly, no impact of gadobutrol dose on rate of AE
incidences was found in these at-risk populations [14].
However, the existing consensus based on prior evidence is that
renal patients are at elevated risk of certain AEs. Reactions to
contrast agents – iodinated as well as gadolinium-based contrast
agents – can be categorized by their pathophysiology into aller-
gy-like, mostly dose-independent and potentially organotoxic,
dose-dependent reactions [23]. At the dose level used in
contrast-enhanced MRI, the likelihood of observing dose-
dependent acute reactions can be considered to be very low.
A boxed warning relating to risk of NSF is included in the
prescribing information at the request of the US Food and
Drug Administration in patients with impaired elimination of
GBCAs, including gadobutrol [24]. While case reports have
described individuals who developed NSF following expo-
sure to gadobutrol, confounders were present in these cases
that may have contributed to NSF development [25–27].
Fig. 2 Gadobutrol-enhanced
magnetic resonance angiography
(MRA) of the head and neck
region, including carotid and
intracranial vessels, scanned with
1.5 Tesla MRI scanner: 50-year-
old male with frequent headaches
but no abnormal findings; MR
angiography in coronal views of
early arterial (a) and late arterial
(b) phases and (c) delayed phase
of MR venography
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GARDIAN is the first large-scale, prospective study to
evaluate the safety of gadobutrol in routine clinical practice,
including at-risk patients, since the gadolinium-related
risks for NSF were reported. Investigators found no
NSF-related symptoms in the study patients, including
patients with renal impairment who were followed up
approximately 3 months later. This is consistent with
retrospective analyses of gadobutrol use in renal im-
paired patients, which found no cases of NSF within a
longer follow-up duration [14, 28]. An ongoing prospec-
tive study (Safety of Gadovist in Renally Impaired
Patients, BGRIP^; NCT00828737) evaluating the safety
of gadobutrol in patients with moderate to severe renal
impairment over a 2-year follow up will further contrib-
ute to understanding the risk of NSF.
One case of fatal anaphylactic shock was assessed to be
related to administration of gadobutrol. To place this event
in perspective, pharmacovigilance data that included 12.67
million gadobutrol administrations reported 17 deaths possi-
bly related to gadobutrol (1.34 deaths per million doses) [29].
This estimated death rate is within the range previously report-
ed for GBCA use in the USA (0.15–2.7 deaths per million




























Study Design Prospective Data collection from
randomized controlled
trials
Surveillance Surveillance Surveillance Surveillance Surveillance Surveillance
Mean dose
(mmol/kg BW)
0.12 NA 0.16 0.1 0.11 NA 0.11 0.22
ADR (%)
Overall rates 0.7 4.0 0.55 2.4 0.4 0.76 0.34 0.93
Nausea/vomiting 0.37 1.6 0.31 0.61 0.23 0.55 0.3 0.50
Heat/warmth 0.03 0.5 0.04 - 0.02 - <0.1 -
Headache 0.01 1.5 0.01 0.44 - - - -
Paraesthesia - 0.1 0.01 0.17 0.02 0.004 <0.1 -
Dizziness 0.10 0.4 0.02 0.19 - - <0.1 -
Focal
convulsions
<0.01 - - - - - - -








<0.01 - 0.07 - - - - -
Flush/
vasodilation
0.01 - 0.01 0.07 - - - -
Cardiovascular
reactions
0.01 - 0.05 - - - - 0.03
Tachycardia,
arrhythmia
0.01 - 0.04 - - - - -
Other symptoms 0.35b >0.0-0.6c 0.2d - 0.1e 0.13f 0.06g 0.17h
a Current study. Includes at-risk population, n= 1,060 (4.5 %)
b Includes rash, pruritus, dyspnoea, chest discomfort, injection site-related symptoms, throat irritation, eyelid oedema, salivary hypersecretion,
dysgeusia, cough, erythema, and other ADRs that occurred with a frequency of <0.01 %
c Includes other ADRs that occurred with a frequency of ≥0.1 %: injection site reaction, dysgeusia, rash, pruritus, erythema, dyspnoea; 0.1 %:
hypersensitivity/anaphylactoid reaction, loss of consciousness, convulsion, parosmia, tachycardia, palpitation, dry mouth, malaise, and feeling cold
d Includes anaphylactic reaction, itching, throat swelling/sore, cough/dyspnoea, hypersalivation, lip swelling, sweating, hoarseness, and other symptoms
e Includes most frequently occurring AE of injection-site pain, pruritus, taste alteration, retching, coughing
f Includes gagging, chest pain, dyspnoea, perioral and periorbital angioneurotic oedema, olfactory hallucinations, itchiness without hives, hypertensive
crisis, sneezing, and loss of bowel control
g Includes pruritus, retching, sweating increased, taste alteration
h Includes coughing, sneezing, abnormal liver function, drug eruption, abnormal sensation
BW, body weight; ADR, adverse drug reaction. Some patients may experience more than one AE symptom.
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doses) [30]. These data indicate that lethal reactions to
gadolinium-based contrast agents are very rare.
Further conclusions from the GARDIAN study are that the
ADRs associated with gadobutrol used in the approved dose
range are unrelated to dose or medical indication. Females had
a slightly higher rate of ADRs than males (0.9 % versus
0.6 %), as reported previously for gadobutrol in a large review
of patients from observational trials and which has been re-
ported for other CM including iodinated agents [13, 31, 32].
Limitations of GARDIAN include the potential for under-
reporting of AEs or ADRs that is typical of non-interventional
studies, in particular for mild AEs and ADRs. In addition,
standards for the monitoring and recognition of AEs and
ADRs may have varied largely between centres. In the
GARDIAN study, due to the non-interventional study design,
the selection of patients to be included was solely at the dis-
cretion of the treating physicians. This might have led to some
selection bias at the individual sites. The strengths of
GARDIAN include the prospective design with a large popu-
lation size enrolled from multiple centres, which helps over-
come the potential bias encountered in AE reports from sin-
gle-centre, single-indication studies. GARDIAN also ad-
dresses the limited research that has been performed to date
on the safety of gadobutrol in Asian countries, as approxi-
mately two thirds of the study population were from this re-
gion. Since Asian patients have a lower average body mass
index [33], they received a lower total gadobutrol dose fol-
lowing weight adjustment than European patients in
GARDIAN. A statistically significant – but not, in our view,
clinically relevant – difference in overall ADR incidence rates
was reported across geographic regions in GARDIAN. Minor
differences in rates of individual ADRs and AEs were also
noted, which may be relevant to practice in different regions.
Conclusions
In the prospective, non-interventional GARDIAN study, gad-
obutrol administered at the recommended dose was very well
tolerated and provided excellent contrast quality in a large,
diverse patient population. Gadobutrol possessed a similar
safety and tolerability profile in adults, patients with renal
impairment or cardiac disease and children. Patients at risk
for CM reaction had a higher incidence of ADRs than other
groups, but without an increased incidence of SAEs.
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